Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Rare Variants Affecting the Fanconi Anaemia DNA Repair Genes Associate with Increased Risk for AML

Kyaw Ze Ya Maung, BSc, Paul Leo, PhD, Anna L Brown, PhD, Mahmoud A Bassal, Bsc, BCompSc, Debora A. Casolari, PhD, Adam Ewing, B.A & PhD, Emma Duncan, PhD, Sarah C Bray, PhD, Evgeny Glazov, PhD, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Russell Saal, MMSc, BSMedTech, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Paula Marlton, MBBS, FRACP, FRCPA, James X Gray, MD PhD, Thomas J Gonda, PhD, Richard D'Andrea, PhD

Blood (2016) 128 (22): 41.

https://doi.org/10.1182/blood.V128.22.41.41

Published: 2016

Journal Articles

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Blood (2015) 126 (23): 1644.

https://doi.org/10.1182/blood.V126.23.1644.1644

Published: 2015

Journal Articles

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

Paula Marlton, MBBS, John F Seymour, MBBS, PhD, Kenneth Bradstock, MBBS, PhD, Ian D Lewis, MB, BS, PhD, Russell Saal, BAppSci, MMedSci, Lyle McMillen, BSc, PhD, Juliana Di Iulio, BAppSc, PhD, Diana Zannino, BSc, MSc, Andrew Grigg, MBBS

Blood (2013) 122 (21): 1444.

https://doi.org/10.1182/blood.V122.21.1444.1444

Published: 2013

Journal Articles

ZAP-70 Expression Measured by Quantitative PCR (QPCR) As a Prognostic Marker in Chronic Lymphocytic Leukaemia (CLL)

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Raymond H. Banh, MBBS, FRACP, FRCPA, Catherine Cheung, Russell Saal, Lynne Chambers, Tennille Pelly, Devinder S Gill, MD

Blood (2011) 118 (21): 4602.

https://doi.org/10.1182/blood.V118.21.4602.4602

Published: 2011

Journal Articles

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaemia (AML).

James X Gray, MD, PhD, Lyle McMillen, PhD, Russell Saal, MMedSc, Steven Lane, MBBS, Peter Mollee, MBBS, Robert Bird, MBBS, Devinder Gill, MBChB, Paula Marlton, MBBS

Blood (2009) 114 (22): 2639.

https://doi.org/10.1182/blood.V114.22.2639.2639

Published: 2009

Journal Articles

JAK2 V617F Mutation Status Predicts Thrombotic Complications, Including Arterial Thrombosis, in Patients with Essential Thrombocytosis (ET).

Helen Weston, MBBS, Robert Bird, MBBS, Vanessa Griffiths, BSc, Mark Jones, BSc, PhD, Karen Grimmett, BSc, Russell Saal, BSc, Anthony K. Mills, MBBS, Devinder Gill, MBBS, Paula Marlton, MBBS, Peter Mollee, MBBS

Blood (2007) 110 (11): 2551.

https://doi.org/10.1182/blood.V110.11.2551.2551

Published: 2007

Journal Articles

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) Monitoring of Minimal Residual Disease (MRD) in Core Binding Factor Acute Myeloid Leukaemia (CBF AML).

Steven W. Lane, Russell Saal, Peter Mollee, Andrew Grigg, Kerry Taylor, John Francis Seymour, Glen Kennedy, Bronwyn Williams, Mark Jones, Karen Grimmett, Vanessa Griffiths, Devinder Gill, Matthew Hourigan, Paula Marlton

Blood (2006) 108 (11): 2296.

https://doi.org/10.1182/blood.V108.11.2296.2296

Published: 2006

Journal Articles

Characterisation and Prognostic Significance of WT-1 Gene Expression in Acute Myeloid Leukemia (AML).

Steven W. Lane, Russell Saal, Suzanne Negus, Peter Mollee, M. Mather, Devinder Gill, Anthony K. Mills, Robert J. Bird, Matthew J. Hourigan, Mark Jones, Paula Marlton

Blood (2006) 108 (11): 2313.

https://doi.org/10.1182/blood.V108.11.2313.2313

Published: 2006

Journal Articles

Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen.

Anthony K. Mills, MBBS, Simon Gibbs, MBBS, Colm Keane, MBBCh BAO, Peter Mollee, MBBS, Karen Grimmett, BApSc, Rosita Van Kuilenburg, Russell Saal, BApSc MMedSci, Devinder Gill, MBChB, H. Miles Prince, MBBS, John F. Seymour, MBBS, Paula Marlton, MBBS

Blood (2004) 104 (11): 5213.

https://doi.org/10.1182/blood.V104.11.5213.5213

Published: 2004

NARROW

Rare Variants Affecting the Fanconi Anaemia DNA Repair Genes Associate with Increased Risk for AML

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

ZAP-70 Expression Measured by Quantitative PCR (QPCR) As a Prognostic Marker in Chronic Lymphocytic Leukaemia (CLL)

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaemia (AML).

JAK2 V617F Mutation Status Predicts Thrombotic Complications, Including Arterial Thrombosis, in Patients with Essential Thrombocytosis (ET).

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) Monitoring of Minimal Residual Disease (MRD) in Core Binding Factor Acute Myeloid Leukaemia (CBF AML).

Characterisation and Prognostic Significance of WT-1 Gene Expression in Acute Myeloid Leukemia (AML).

Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only